1429129-68-9

Usage

Uses

Used in Pharmaceutical Industry:
3-(3,5-dimethyl-1,2-oxazol-4-yl)-5-[hydroxyl(phenyl)methyl]phenol is used as a bromodomain ligand for its selective inhibitory action on the first bromodomain of BRD4. This application is significant because it has shown potential in decreasing the lifespan of lung adenocarcinoma cell lines and reducing cell proliferation in leukemia cells, making it a promising candidate for cancer treatment and therapy.
Used in Drug Development:
In the field of drug development, 3-(3,5-dimethyl-1,2-oxazol-4-yl)-5-[hydroxyl(phenyl)methyl]phenol can be utilized as a starting point for the design and synthesis of novel compounds with improved pharmacological properties. Its unique structure and functional groups may allow for the development of new drugs with enhanced efficacy and selectivity, particularly in the treatment of cancer and other diseases.
Used in Chemical Research:
3-(3,5-dimethyl-1,2-oxazol-4-yl)-5-[hydroxyl(phenyl)methyl]phenol can also be employed in chemical research as a model compound to study the interactions between small molecules and biological targets. Understanding these interactions can provide valuable insights into the design of new drugs and the development of targeted therapies for various diseases.

Upstream product

• 16114-47-9 3,5-dimethylisoxazole-4-boronic acid 
• 199177-26-9 3-bromo-5-hydroxybenzaldehyde 
• 1020336-51-9 3-bromo-5-hydroxybenzyl alcohol 
• 140472-69-1 3-bromo-5-hydroxy-benzoic acid 
• 1429129-61-2 3-(3,5-dimethylisoxazol-4-yl)-5-hydroxybenzaldehyde 
• 100-58-3 phenylmagnesium bromide 

Downstream Products

• 1429129-71-4 OFXBD₀₃ 
• 1429129-72-5 (3-(3,5-dimethylisoxazol-4-yl)-5-hydroxyphenyl)(phenyl)methanone 

Relevant academic research and scientific papers

BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability

Ligands for the bromodomain and extra-terminal domain (BET) family of bromodomains have shown promise as useful therapeutic agents for treating a range of cancers and inflammation. Here we report that our previously developed 3,5-dimethylisoxazole-based BET bromodomain ligand (OXFBD02) inhibits interactions of BRD4(1) with the RelA subunit of NF-κB, in addition to histone H4. This ligand shows a promising profile in a screen of the NCI-60 panel but was rapidly metabolised (t? = 39.8 min). Structure-guided optimisation of compound properties led to the development of the 3-pyridyl-derived OXFBD04. Molecular dynamics simulations assisted our understanding of the role played by an internal hydrogen bond in altering the affinity of this series of molecules for BRD4(1). OXFBD04 shows improved BRD4(1) affinity (IC50 = 166 nM), optimised physicochemical properties (LE = 0.43; LLE = 5.74; SFI = 5.96), and greater metabolic stability (t? = 388 min).

Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands

The bromodomain protein module, which binds to acetylated lysine, is emerging as an important epigenetic therapeutic target. We report the structure-guided optimization of 3,5-dimethylisoxazole derivatives to develop potent inhibitors of the BET (bromodom